NCT00699712View on ClinicalTrials.gov

Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Acute Decompensated Heart Failure
Interventions
DRUG

CD-NP (Chimeric natriuretic peptide)

Infusion of CDNP at two of four doses

Trial Locations (1)

121552

Russian Academy of Medical Sciences, Moscow

Sponsors

Lead Sponsor

Nile Therapeutics
All Listed Sponsors
collaborator

Momentum Research, Inc.

INDUSTRY

lead

Nile Therapeutics

INDUSTRY

NCT00699712 - Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF) | Biotech Hunter | Biotech Hunter